Adherence to TKI in CML patients: more than reports
- 153 Downloads
There has been much debate about reliable methodologies for measuring adherence to drug therapies for chronic diseases. Recently, our group carried out a drug adherence study  with chronic myeloid leukemia (CML), a clonal myeloproliferative disease characterized by the presence of the Philadelphia chromosome . Tyrosine kinase inhibitors (TKI) are widely used to treat CML and have been shown to lead to long-term survival rates when administered with strict dosage regimens. Thus, assuring treatment adherence is a critical strategy to obtain successful outcomes in patients with this chronic disease.
We have posited that the clinical pharmacist can play a critical role in the present treatment plans through more frequent patient monitoring and by providing more personalized assessments of the patient’s disease status . Because the characteristics of TKI treatments for CML are similar to other chronic disease treatments, an effective adherence methodology demonstrated for CML...
This work was partially supported by a FAPES grant (0461/2015).
Compliance with ethical standards
Conflict of interest
We declare that FAPES foundation did not participate in authorship, data acquisition, analysis, decision concerning the procedures, or conclusions of the work in any form. As such, the authors of this manuscript have full control of the primary data and agree to make the data available for review by journal editors if requested.
- 1.Moulin, SMM, Eutrópio, JF, Souza, JO et al (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Supp care Cancer 25:951–955Google Scholar
- 3.Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergílio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, Souza CA, Pagnano KB (2015) Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. Clinics 70(8):550–555. https://doi.org/10.6061/clinics/2015(08)04 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Okumura LM, Antunes VD, Aguiar KSet al (2015) Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment. Pharm Pract (Granada) 13(2): 559, DOI: 10.18549/PharmPract.2015.02.559
- 6.Okumura, L.M (2017) How to report adherence to treatment as clinically relevant data - making a case of CML and TKI. Supp Care Cancer. https://doi.org/10.1007/s00520-017-3809-2
- 7.WHO Adherence to Long-term Therapies Project (2003) Adherence to long-term therapies: evidence for action. World Health Organization, GenèveGoogle Scholar